98 related articles for article (PubMed ID: 10451534)
1. Dimerization of urinary beta-core/hCFbetacf: a cause of poor beta-core assay performance in Down syndrome screening studies.
Iles RK; Butler SA; Jacoby E
Prenat Diagn; 1999 Aug; 19(8):790-2. PubMed ID: 10451534
[No Abstract] [Full Text] [Related]
2. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies.
Cole LA; Acuna E; Isozaki T; Palomaki GE; Bahado-Singh RO; Mahoney MO
Prenat Diagn; 1997 Dec; 17(12):1125-33. PubMed ID: 9467809
[TBL] [Abstract][Full Text] [Related]
3. Screening for Down syndrome using urine hCG free beta-subunit in the second trimester of pregnancy.
Cole LA; Jacobs M; Isozaki T; Palomaki GE; Bahado-Singh RO; Mahoney MJ
Prenat Diagn; 1997 Dec; 17(12):1107-11. PubMed ID: 9467807
[TBL] [Abstract][Full Text] [Related]
4. Stability of hCG free beta-subunit and beta-core fragment in urine.
Cole LA
Prenat Diagn; 1997 Feb; 17(2):185-7. PubMed ID: 9061770
[No Abstract] [Full Text] [Related]
5. Levels of urinary beta-core fragment, total oestriol, and the ratio of the two in second-trimester screening for Down syndrome.
Kellner LH; Canick JA; Palomaki GE; Neveux LM; Saller DN; Walker RP; Osathanondh R; Bombard AT
Prenat Diagn; 1997 Dec; 17(12):1135-41. PubMed ID: 9467810
[TBL] [Abstract][Full Text] [Related]
6. Serum hyperglycosylated hCG: a potential screening test for fetal Down syndrome.
Shahabi S; Oz UA; Bahado-Singh RO; Mahoney MJ; Omrani A; Baumgarten A; Cole LA
Prenat Diagn; 1999 May; 19(5):488-9. PubMed ID: 10360522
[No Abstract] [Full Text] [Related]
7. Urinary beta-core-hCG screening in the first trimester.
Cuckle HS; Canick JA; Kellner LH; Van Lith JM; White I; Helbig BR; Rose NC; Sehmi IK; Jones R
Prenat Diagn; 1996 Nov; 16(11):1057-9. PubMed ID: 8953643
[No Abstract] [Full Text] [Related]
8. Oligosaccharide variants of hCG-related molecules: potential screening markers for Down syndrome.
Cole LA; Cermik D; Bahado-Singh R
Prenat Diagn; 1997 Dec; 17(12):1188-90. PubMed ID: 9467819
[No Abstract] [Full Text] [Related]
9. Urinary screening tests for fetal Down syndrome: I. Fresh beta-core fragment.
Cole LA; Rinne KM; Mahajan SM; Oz UA; Shahabi S; Mahoney MJ; Bahado-Singh RO
Prenat Diagn; 1999 Apr; 19(4):340-50. PubMed ID: 10327140
[TBL] [Abstract][Full Text] [Related]
10. Integrated screening for Down's syndrome.
Chen FM
J Fam Pract; 1999 Nov; 48(11):846-7. PubMed ID: 10907617
[No Abstract] [Full Text] [Related]
11. [Human chorionic gonadotropin beta-core fragment (hCGbetacf)].
Okamoto T
Nihon Rinsho; 2005 Aug; 63 Suppl 8():765-7. PubMed ID: 16149635
[No Abstract] [Full Text] [Related]
12. [Antenatal screening for Down syndrome: a smattering of epidemiology].
Boulvain M; Billieux MH; Irion O
Rev Med Suisse; 2008 Oct; 4(176):2276-8, 2280. PubMed ID: 19025178
[TBL] [Abstract][Full Text] [Related]
13. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
14. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
15. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
16. [Prenatal diagnosis of Down's syndrome: prediction from maternal serum markers].
Zilberstein T; Maymon E
Harefuah; 1998 Mar; 134(5):393-6. PubMed ID: 10909560
[No Abstract] [Full Text] [Related]
17. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Down's syndrome screening population data sets by simulation: analyser-specific parameters may be superior to meta-analysis-derived parameters.
Reynolds TM; Vranken G; Van Nueten J; Aldis J
Int J Clin Pract; 2008 May; 62(5):735-43. PubMed ID: 17590221
[TBL] [Abstract][Full Text] [Related]
19. Is screening for fetal anomalies reliable in HIV-infected pregnant women? A multicentre study.
Brossard P; Boulvain M; Coll O; Barlow P; Aebi-Popp K; Bischof P; Martinez de Tejada B; ;
AIDS; 2008 Oct; 22(15):2013-7. PubMed ID: 18784463
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome.
Spencer K
Ann Clin Biochem; 2001 Jul; 38(Pt 4):413-4. PubMed ID: 11471889
[No Abstract] [Full Text] [Related]
[Next] [New Search]
